高级搜索

人巨细胞病毒感染对围手术期尿路上皮癌患者免疫功能的影响

李法锦, 施浩强, 唐 亮, 张 涛, 樊 松, 江长琴, 葛 俊, 王明丽, 梁朝朝

李法锦, 施浩强, 唐 亮, 张 涛, 樊 松, 江长琴, 葛 俊, 王明丽, 梁朝朝. 人巨细胞病毒感染对围手术期尿路上皮癌患者免疫功能的影响[J]. 肿瘤防治研究, 2014, 41(02): 119-123. DOI: 10.3971/j.issn.1000-8578.2014.02.006
引用本文: 李法锦, 施浩强, 唐 亮, 张 涛, 樊 松, 江长琴, 葛 俊, 王明丽, 梁朝朝. 人巨细胞病毒感染对围手术期尿路上皮癌患者免疫功能的影响[J]. 肿瘤防治研究, 2014, 41(02): 119-123. DOI: 10.3971/j.issn.1000-8578.2014.02.006
LI Fajin, SHI Haoqiang△, TANG Liang, ZHANG Tao, FAN Song, JIANG Changqin, GE Jun, WANG Mingli, LIANG Chaozhao. Impact of Human Cytomegalovirus Infection on Immune Function of Urothelial Carcinoma Patients in Perioperative Period[J]. Cancer Research on Prevention and Treatment, 2014, 41(02): 119-123. DOI: 10.3971/j.issn.1000-8578.2014.02.006
Citation: LI Fajin, SHI Haoqiang△, TANG Liang, ZHANG Tao, FAN Song, JIANG Changqin, GE Jun, WANG Mingli, LIANG Chaozhao. Impact of Human Cytomegalovirus Infection on Immune Function of Urothelial Carcinoma Patients in Perioperative Period[J]. Cancer Research on Prevention and Treatment, 2014, 41(02): 119-123. DOI: 10.3971/j.issn.1000-8578.2014.02.006

人巨细胞病毒感染对围手术期尿路上皮癌患者免疫功能的影响

基金项目: 国家临床重点专科(泌尿外科)建设项目
详细信息
    作者简介:

    李法锦(1986-),女,硕士,主管技师,主要从事临床分子病毒的研究

    施浩强(1971-),男,硕士,副教授,副主任医师,主要从事膀胱癌研究(△:并列第一作者)

    通讯作者:

    梁朝朝,E-mail:liang_chaochao@163.com

  • 中图分类号: R 737.14

Impact of Human Cytomegalovirus Infection on Immune Function of Urothelial Carcinoma Patients in Perioperative Period

  • 摘要: 目的 检测围手术期尿路上皮癌患者外周血的CD3+、CD4+、CD8+T淋巴细胞比例和人类巨细胞病毒(HCMV)IgG和IgM抗体,了解近期HCMV感染对围手术期尿路上皮癌患者细胞免疫功能的影响。方法 采集33例经病理检测确诊为尿路上皮癌的患者外周血,流式细胞仪检测外周血CD3+、CD4+和CD8+ T细胞亚群比例,血浆ELISA法定性检测HCMV-IgG和HCMV-IgM抗体,根据HCMV-IgM抗体结果将尿路上皮癌患者分为阳性组和阴性组,比较两组患者的T细胞亚群有无差异。结果 33例患者中HCMV-IgG抗体阳性31例;HCMV-IgM抗体阳性7例,阴性26例。HCMV-IgM阳性组和阴性组之间的CD3+、CD4+ 和CD8+ T细胞亚群有着显著的差异(P<0.01)。阳性组患者的CD4+ T细胞的百分比显著低于阴性组,并且该组CD4+/CD8+比值亦显著低于阴性组。CD4+/CD8+的比值提示阳性组中有85%(6/7)的患者处于免疫功能低下状态,而相对于阴性组仅有11.5%(3/23)的患者处于免疫功能低下状态,两组间差异有统计学意义(P<0.01)。结论 术前检测HCMV-IgM可以很好地预测尿路上皮癌患者的细胞免疫功能,对术后辅助治疗具有指导意义。

     

    Abstract: Objective To detect the ratio of CD3+, CD4+, CD8+ T lymphocytes and HCMV-IgG and IgM antibodies in peripheral blood of urothelial carcinoma patients in perioperative period and to evaluate the impact of HCMV infection on immune functions. Methods Thirty-three peripheral blood samples were collected from urothelial carcinoma patients with pathological diagnosis. Flow cytometry was performed to detect the ratio of CD3+, CD4+ and CD8+ T lymphocytes subsets. ELISA was conducted to detect HCMVIgG and IgM antibodies. Patients were divided into positive group and negative group based on HCMVIgM results. T lymphocyte difference was also compared. Results HCMV-IgG antibodies of 31 patients were positively expressed, HCMV-IgM antibodies of 7 patients were positively expressed, and HCMV-IgM antibodies of 26 patients were negatively expressed respectively. CD3+, CD4+ and CD8+ T lymphocytes subsets were statistically different between HCMV-IgM positive and negative groups(P<0.01). The percentage of CD4+ T lymphocytes and CD4+/CD8+ ratio of positive group were obviously less than those of negative group. CD4+/CD8+ ratio showed that the immune function of 85% (6/7) positive group was poor, while there was only 11.5% (3/23) in negative group. There was a statistical difference between two groups (P<0.01). Conclusion Detecting HCMV-IgM preoperatively may predict the cellular immune functions of patients with urothelial carcinoma, contributing to perform adjuvant therapy after operation

     

  • [1] Wen DG, Shan BE, Zhang SW, et al. Analysis of incidence and mortality rates of bladder cancer in registration areas of China from 2003 to 2007[J]. Zhong Liu,2012,32(4):256-62. [温登瑰, 单保恩,张思维,等,2003—2007年中国肿瘤登记地区膀胱 癌的发病与死亡分析[J]. 肿瘤, 2012,32(4):256-62.]
    [2] Oosterlinck W, Decaestecker K. Current strategies in the treatment of non-muscle-invasive bladder cancer[J]. Expert Rev Anticancer Ther,2012,12(8):1097-106.
    [3] Cui Y, Wang ML. Research in human cytomegalovirus infection and cancer[J]. Wei Sheng Wu Yu Gan Ran,2008,3(3):166-9.[崔 寰,王明丽.人巨细胞病毒感染与肿瘤相关性研究进展[J]. 微生 物与感染,2008,3(3):166-9.]
    [4] Yang N,Chen HL,Qian X,et al. Analysis of Nanchang qualifi ed blood donors with human cytomegalovirus infection[J]. Zhongguo Shu Xue Za Zhi,2012,25(11):1193-4.[杨南,陈火玲,钱 献,等.南昌市合格无偿献血者人巨细胞病毒感染情况分析[J]. 中国输血杂志,2012,25(11):1193-4.]
    [5] Huang LS,Sheng CH,Lin MS. Investigate in Shantou blood donors with HCMV[J]. Guangzhou Yi Yao,2009,40(5):63-4.[黄 蓝生,盛楚华,林美珊. 汕头市健康无偿献血人群HCMV感染调 查[J] 广州医药,2009,40(5):63-4.]
    [6] Zhou YF, Fang F. Molecular mechanisms of HCMV in immune escape[J]. Guo Wai Yi Xue (Bing Du Xue Fen Ce), 2004, 11 (2):43-6. [周玉峰,方峰. HCMV免疫逃避分子机制研究进展 [J] 国外医学(病毒学分册),2004,11(2):43-6.]
    [7] Moutaftsi M, Mehl AM, Borysiewicz LK, et al. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells[J]. Blood, 2002, 99(8):2913-21.
    [8] Hansen SG, Powers CJ, Richards R, et al. Evasion of CD8+ T cells is critical for super-infection by cytomegalovirus[J]. Scince, 20 10,328(5974):102-6.
    [9] Kawai K, Miyazaki J, Joraku A,et al. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine[J].Cancer Sci,2013,104(1):22-7.
    [10] Zuiverloon TC, Nieuweboer AJ, Vékony H, et al. Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review[J]. Eur Urol,2012,61(1):128-45.
    [11] Shintani Y, Sawada Y, Inagaki T, et al. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy[J]. Int J Urol,2007,14(2):140-6.
    [12] Shi HQ,Ge J,Tang L,et al. The correlation study of HCMV active infection and urothelial carcinoma[J]. Anhui Yi Ke Da Xue Xue Bao,2013,48(1):60-5.[施浩强,葛俊,唐亮,等. HCMV 活动性感染与尿路上皮癌的相关性研究[J].安徽医科大学学 报,2013,48(1):60-5.]
计量
  • 文章访问数:  1438
  • HTML全文浏览量:  319
  • PDF下载量:  486
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-09-02
  • 修回日期:  2013-10-29
  • 刊出日期:  2014-02-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭